TREATMENT.COM AI INC. ANNOUNCES CLOSING OF UPSIZED BROKERED LIFE OFFERING OF UNITS
Treatment.com AI Inc. (OTC: TREIF) has successfully closed its upsized brokered private placement, raising $3.3 million through the issuance of 6,600,000 units at $0.50 per unit. Each unit includes one common share and half a share purchase warrant, with warrants exercisable at $0.75 until March 13, 2027.
The company paid the underwriter, Ventum Capital Corp., a cash commission of $264,000 and issued 528,000 non-transferable broker warrants. The proceeds will be allocated to sales and administrative expenses, software research and development, and working capital purposes.
Treatment.com AI specializes in healthcare AI technology, having developed the Global Library of Medicine (GLM), an AI engine built with input from hundreds of healthcare professionals. The GLM platform provides clinical information, recommended tests, and billing codes to healthcare professionals, aiming to reduce administrative burden and improve patient care quality.
Treatment.com AI Inc. (OTC: TREIF) ha concluso con successo il suo collocamento privato brokerato ampliato, raccogliendo 3,3 milioni di dollari attraverso l'emissione di 6.600.000 unità a 0,50 dollari per unità. Ogni unità include una azione comune e mezza opzione di acquisto di azioni, con opzioni esercitabili a 0,75 dollari fino al 13 marzo 2027.
L'azienda ha pagato all'intermediario, Ventum Capital Corp., una commissione in contante di 264.000 dollari e ha emesso 528.000 warrant broker non trasferibili. I proventi saranno destinati a spese di vendita e amministrative, ricerca e sviluppo software e scopi di capitale circolante.
Treatment.com AI è specializzata nella tecnologia AI per la salute, avendo sviluppato la Global Library of Medicine (GLM), un motore AI costruito con input da centinaia di professionisti sanitari. La piattaforma GLM fornisce informazioni cliniche, test raccomandati e codici di fatturazione ai professionisti della salute, con l'obiettivo di ridurre il carico amministrativo e migliorare la qualità dell'assistenza ai pazienti.
Treatment.com AI Inc. (OTC: TREIF) ha cerrado con éxito su colocación privada brokerada ampliada, recaudando 3.3 millones de dólares a través de la emisión de 6,600,000 unidades a 0.50 dólares por unidad. Cada unidad incluye una acción común y media opción de compra de acciones, con opciones ejercitables a 0.75 dólares hasta el 13 de marzo de 2027.
La empresa pagó al suscriptor, Ventum Capital Corp., una comisión en efectivo de 264,000 dólares y emitió 528,000 warrants de broker no transferibles. Los ingresos se destinarán a gastos de ventas y administrativos, investigación y desarrollo de software, y fines de capital de trabajo.
Treatment.com AI se especializa en tecnología de IA para la salud, habiendo desarrollado la Global Library of Medicine (GLM), un motor de IA construido con aportes de cientos de profesionales de la salud. La plataforma GLM proporciona información clínica, pruebas recomendadas y códigos de facturación a los profesionales de la salud, con el objetivo de reducir la carga administrativa y mejorar la calidad de la atención al paciente.
Treatment.com AI Inc. (OTC: TREIF)는 성공적으로 확대된 중개 사모 배정을 마감하고 330만 달러를 조달하였습니다. 이는 단위당 0.50달러에 6,600,000 단위를 발행한 것입니다. 각 단위에는 하나의 보통주와 반 개의 주식 매수 권리가 포함되어 있으며, 권리는 2027년 3월 13일까지 0.75달러에 행사할 수 있습니다.
회사는 인수인인 Ventum Capital Corp.에 264,000달러의 현금 수수료를 지급하고 528,000개의 양도 불가능한 중개 권리를 발행했습니다. 수익금은 판매 및 관리 비용, 소프트웨어 연구 및 개발, 운영 자본 용도로 사용될 것입니다.
Treatment.com AI는 의료 AI 기술을 전문으로 하며, 수백 명의 의료 전문가의 의견을 바탕으로 구축된 Global Library of Medicine (GLM)을 개발했습니다. GLM 플랫폼은 임상 정보, 추천 검사 및 청구 코드를 의료 전문가에게 제공하여 행정 부담을 줄이고 환자 치료 품질을 개선하는 것을 목표로 하고 있습니다.
Treatment.com AI Inc. (OTC: TREIF) a réussi à clore son placement privé brokeré élargi, levant 3,3 millions de dollars grâce à l'émission de 6 600 000 unités à 0,50 dollar par unité. Chaque unité comprend une action ordinaire et une demi-option d'achat d'actions, les options étant exerçables à 0,75 dollar jusqu'au 13 mars 2027.
L'entreprise a versé à l'underwriter, Ventum Capital Corp., une commission en espèces de 264 000 dollars et a émis 528 000 warrants de courtier non transférables. Les produits seront affectés aux frais de vente et administratifs, à la recherche et au développement de logiciels, ainsi qu'à des fins de fonds de roulement.
Treatment.com AI se spécialise dans la technologie d'IA pour la santé, ayant développé la Global Library of Medicine (GLM), un moteur d'IA construit avec les contributions de centaines de professionnels de la santé. La plateforme GLM fournit des informations cliniques, des tests recommandés et des codes de facturation aux professionnels de la santé, visant à réduire la charge administrative et à améliorer la qualité des soins aux patients.
Treatment.com AI Inc. (OTC: TREIF) hat erfolgreich seine erweiterte vermittelte Privatplatzierung abgeschlossen und 3,3 Millionen Dollar durch die Ausgabe von 6.600.000 Einheiten zu je 0,50 Dollar pro Einheit gesammelt. Jede Einheit umfasst eine Stammaktie und eine halbe Kaufoption, die bis zum 13. März 2027 zu 0,75 Dollar ausgeübt werden kann.
Das Unternehmen zahlte dem Underwriter, Ventum Capital Corp., eine Bargeldprovision von 264.000 Dollar und gab 528.000 nicht übertragbare Broker-Warrants aus. Die Erlöse werden für Vertriebs- und Verwaltungskosten, Softwareforschung und -entwicklung sowie Betriebskapital verwendet.
Treatment.com AI ist auf KI-Technologie im Gesundheitswesen spezialisiert und hat die Global Library of Medicine (GLM) entwickelt, eine KI-Engine, die mit Beiträgen von Hunderten von Gesundheitsfachleuten erstellt wurde. Die GLM-Plattform bietet klinische Informationen, empfohlene Tests und Abrechnungscodes für Gesundheitsfachleute und zielt darauf ab, die administrative Belastung zu reduzieren und die Qualität der Patientenversorgung zu verbessern.
- Successful capital raise of $3.3 million through private placement
- No hold period on units issued under Listed Issuer Financing Exemption
- Development of comprehensive AI healthcare platform (GLM) with 10,000+ expert medical reviews
- Share dilution through issuance of 6.6 million new units
- Additional potential dilution from 3.3 million warrants at $0.75
- Significant underwriting costs ($264,000 cash plus 528,000 broker warrants)
Vancouver, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that further to its news releases dated February 27, 2025 and March 3, 2025, it has closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the “Offering”) with Ventum Capital Corp., (the “Underwriter”) who acted as underwriter pursuant to an underwriting agreement dated March 13, 2025 (the “Underwriting Agreement”).
Dr. Essam Hamza, the Chief Executive Officer of Treatment, added: "We would like to thank the shareholders for the strong demand shown for this financing. I would also like to thank the teams at Ventum and Treatment for all the hard work they have put into getting this significant deal across the finish line. The added money will help us expedite our ambitious growth plans and we look forward to updating the market accordingly.”
Pursuant to the Offering, the Company issued 6,600,000 units (the “Units”) at the issue price of
The Offering was completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exemptions (the “Listed Issuer Financing Exemption”) and therefore the Units issued pursuant to the Offering are not subject to a hold period in accordance with applicable Canadian securities laws. There is an amended and restated offering document (the "Offering Document") related to the Offering that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at www.treatment.com. Prospective investors should read this Offering Document before making an investment decision.
The Company intends to use the proceeds from the Offering for sales and administrative expenses, software research and development and working capital purposes.
Pursuant to the Underwriting Agreement, the Company paid to the Underwriter a cash commission of
The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
ehamza@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements relating to the Offering and to future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, any statements regarding the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include risks detailed from time to time in the filings made by Treatment with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
FAQ
How much did Treatment.com AI (TREIF) raise in their March 2025 private placement?
What are the terms of the warrants issued in Treatment.com AI's March 2025 offering?
How will Treatment.com AI (TREIF) use the proceeds from the March 2025 offering?
What is Treatment.com AI's Global Library of Medicine (GLM) platform?
